$IRON Cashflow Statement | Understand Stock

$IRON

$77.66 +$3.15 (4.23%) Close

$IRON Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operations:
Depreciation expense
Gain on the sale of property and equipment
Depreciation and amortization
Stock-based compensation
Loss on conversion of convertible notes
Accretion of discount on convertible notes
Noncash license expense
Change in fair value of derivative liability
Amortization/accretion of investment securities
Loss from initial consolidation of variable interest entity
Non-cash lease expense
Non-cash interest expense
Other non-cash items

Prepaid expenses and other current assets
Deferred offering costs
Other assets
Accounts payable
Accrued expenses and other current liabilities
Accrued expenses
Accrued external research and development expenses
Other accrued expenses
Operating lease liabilities
Net cash used in operating activities

Cash flows from investing activities:
Purchases of marketable securities
Maturities of marketable securities
Purchases of property and equipment
Proceeds from the sale of property and equipment
Net cash used in investing activities

Cash flows from financing activities:
Proceeds from Business Combination, net
Proceeds from sale of common stock in underwritten offerings, net of issuance costs paid
Proceeds from sale of pre-funded warrants in underwritten offerings, net of issuance costs paid
Proceeds from sale of common stock in at-the-market offerings, net of issuance costs paid
Proceeds from issuance of long-term debt, net of issuance costs paid
Payment of debt issuance costs
Proceeds from the issuance of common stock in pre-closing financing
Cash acquired in connection with the reverse recapitalization
Payment of reverse recapitalization transaction costs
Proceeds from issuance of convertible preferred stock, net of issuance costs
Proceeds from convertible notes
Proceeds from stock option exercises
Principal payments on term loan
Contributions from employee stock purchase plan
Net cash provided by financing activities
Net (decrease) increase in cash, cash equivalents and restricted cash

Cash, cash equivalents and restricted cash, beginning of period
Cash, cash equivalents and restricted cash, end of period
Supplemental cash flow information
Cash paid for income taxes
Cash paid for interest
Cash paid for amounts included in the measurement of operating lease liabilities
Purchases of property and equipment included in accounts payable and accrued expenses
Right-of-use assets obtained in exchange for new operating lease liabilities
Net decrease in right-of-use assets related to lease
Net decrease in right-of-use assets related to lease modifications and reassessment events
Net decrease in operating lease liabilities due to lease modifications and reassessment events
Deferred issuance costs on Series B convertible preferred stock in accounts payable and accruals
Deferred offering costs included in accounts payable and accruals at end of period
Net increase (decrease) in right-of-use assets related to lease modifications and reassessment events
Net increase (decrease) in operating lease liabilities related to lease modifications and reassessment events
Deferred issuance costs on sale of pre-funded warrants in registered direct offering included in accounts payable and accrued expenses
Receivable for proceeds from stock option exercises included in other current assets
Deferred issuance costs on sale of common stock and pre-funded warrants in offerings included in accounts payable and accrued expenses
Settlement of derivative liability upon issuance of common stock to Roche
Conversion of convertible notes to Series B preferred stock
Exercise of warrants
Proceeds from exercise of stock options included in other current assets
Proceeds from the sale of property and equipment included in other current assets
Discount on convertible notes
Deferred offering costs included in accounts payable and accrued expenses and other current liabilities

Comments